

Kaiser Foundation Health Plan of Washington Kaiser Foundation Health Plan of Washington Options, Inc. Provider Communications, RCR-A3W-04 PO Box 34262, Seattle WA 98124-1262

MAY 21, 2024

LYMPHOCYTE IMMUNE GLOBULIN (ATGAM) WILL REQUIRE PRIOR AUTHORIZATION APPROVAL

Dear Provider,

Effective September 1, 2024, Lymphocyte immune globulin (Atgam) will be added to the non-Medicare list of office administered drugs requiring prior authorization. This letter is a notification of the upcoming change in prior authorization criteria required before administering this medication under the medical benefit.

Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington, Options, Inc. (Kaiser Permanente) require prior authorization for a select group of injectable drugs that may be administered under the medical benefit in a physician's office or by home infusion. These reviews are intended to ensure consistent benefit adjudication as well as appropriate utilization in accordance with the Kaiser Permanente Pharmacy & Therapeutics Committee's evidence-based criteria for coverage.

Prior Authorization Criteria for Lymphocyte immune globulin (Atgam):

DRUG NAME	COVERAGE CRITERIA
LYMPHOCYTE IMMUNE GLOBULIN	Treatment of patients with lower risk symptomatic myelodysplastic syndromes (MDS) who meet ALL of the following:
	 Without del(5q) With ring sideroblasts less than 15% or less than 5% if SF3B1 mutation Serum erythropoietin (epo) greater than 500 mU/mL

Additional Information

A complete list of office-administered injectable drugs requiring prior authorization can be found on the Kaiser Permanente provider website at

https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/officeinject.

To request prior authorization review, please use the Referral Request online form (login required) located on the Kaiser Permanente provider website at https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice.

You can also fax your request to the Review Services department toll-free at 1-888-282-2685.

Thank you for the care you provide to our members, your patients. If you have any questions about this process, please call Review Services at 1-800-289-1363, Monday through Friday from 8 a.m. to 5 p.m.

Sincerely,

·UIA

Ravi Ubriani, MD, Chair Pharmacy & Therapeutics Committee